Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2018
19th World Conference on Lung Cancer
Access to all presentations that occur during the 19th World Conference on Lung Cancer in Toronto, ON
Presentation Date(s):- Sept 23 - 26, 2018
- Total Presentations: 2384
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
MA22 - New Therapeutics, Pathology, and Brain Metastases for Small Cell and Neuroendocrine Tumour
- Type: Mini Oral Abstract Session
- Track: Small Cell Lung Cancer/NET
- Presentations: 12
- Coordinates: 9/25/2018, 15:15 - 16:45, Room 206 BD
-
+
MA22.01 - PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency
15:15 - 15:20 | Presenter: Benjamin H Lok
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.02 - Activation of MAPK Suppresses Neuroendocrine Transcription Factors and Causes Transdifferentiation of Small Cell Lung Cancer
15:20 - 15:25 | Presenter: Yusuke Inoue
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.03 - SCLC Circulating Tumour Cell Derived Explants: The Clinical Characteristics of Patients Whose Samples Generate CDX
15:25 - 15:30 | Presenter: Alexander John Vickers
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.04 - Discussant - MA 22.01, MA 22.02, MA 22.03
15:30 - 15:45 | Presenter: Céline Mascaux
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.05 - Impact of Tumor Spread Through Air Spaces (STAS) in Lung Neuroendocrine Tumors (NETs)
15:45 - 15:50 | Author(s): Rania Gaber Aly
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.06 - Preinvasive Multifocal Neuroendocrine Lesions with Primary Typical Carcinoid Lung Tumors: A Negative Prognostic Factor?
15:50 - 15:55 | Presenter: Niccolo Daddi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.07 - Prognostic Value of Distant Organ-Specific Metastases in Newly Diagnosed Lung Neuroendocrine Tumors: A Population-Based Study
15:55 - 16:00 | Author(s): Junmiao Wen
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.08 - Discussant - MA 22.05, MA 22.06, MA 22.07
16:00 - 16:15 | Presenter: Giuseppe Pelosi
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.09 - Should Stereotactic Radiosurgery be Considered for Salvage of Intracranial Recurrence in Small Cell Lung Cancer?
16:15 - 16:20 | Presenter: Brooklyn Mazure
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.10 - Prevalence and Risk Factors of Brain Metastases in Limited Stage Small Cell Lung Cancer Immediately Before Prophylactic Cranial Irradiation
16:20 - 16:25 | Author(s): Xiao Chu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.11 - Risk of Hippocampal Metastases in Small Cell Lung Cancer: Implications for Hippocampal Sparing Cranial Irradiation
16:25 - 16:30 | Presenter: Rachel Effeney
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA22.12 - Discussant - MA 22.09, MA 22.10, MA 22.11
16:30 - 16:45 | Presenter: Houda Bahig
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MS20 - Innovative and Evolving Strategies in Diagnosis and Management of Stage I NSCLC
- Type: Mini Symposium
- Track: Treatment of Early Stage/Localized Disease
- Presentations: 6
- Coordinates: 9/25/2018, 15:15 - 16:45, Room 202 BD
-
+
MS20.01 - Robotic and Innovative Surgery
15:15 - 15:30 | Presenter: Waël C. Hanna
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS20.02 - The Future of Stereotactic Ablative Radiotherapy (SABR)
15:30 - 15:45 | Presenter: Billy W Loo
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS20.03 - Immunotherapy and Surgery: Neoadjuvant or Adjuvant? Is It Safe?
15:45 - 16:00 | Presenter: Jamie E Chaft
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS20.04 - Prediction of Clinical Outcome in NSCLC Using Integrative Genomics: Implications for Adjuvant Chemotherapy
16:00 - 16:15 | Presenter: Phillippe Broet
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS20.05 - Beyond Surgery - Support of the Surgical Patient
16:15 - 16:30 | Presenter: Kate Kuhns
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS20.06 - Less Is More: Segmentectomy in the Management of Early Stage NSCLC
16:30 - 16:45 | Presenter: Shun-ichi Watanabe
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MS21 - Giants in Thoracic Oncology
- Type: Mini Symposium
- Track:
- Presentations: 9
- Coordinates: 9/25/2018, 15:15 - 17:00, Room 105
-
+
MS21.01 - Surgery and its Evolution
15:15 - 15:25 | Presenter: Paul Emile Van Schil
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS21.02 - Chemotherapy through the 21st Century
15:25 - 15:35 | Presenter: David H Johnson
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS21.03 - Revolution in Radiation
15:35 - 15:45 | Presenter: Ben Slotman
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS21.04 - Targeted Therapy - The Second Revolution
15:45 - 15:55 | Presenter: Frances A Shepherd
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS21.05 - Quality of Life - Are we Paying Enough Attention?
15:55 - 16:05 | Presenter: Richard J Gralla
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS21.06 - Immunotherapy - Sequence or Combination?
16:05 - 16:15 | Presenter: Roy S. Herbst
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS21.07 - The Growing Role of Biomarkers in Treatment Selection: “The Tissue is the Issue”
16:15 - 16:25 | Presenter: Fred R. Hirsch
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS21.08 - Where will we be in 10 years?
16:25 - 16:35 | Presenter: Paul A. Bunn, Jr.
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS21.09 - Discussion
16:35 - 17:00
- Abstract
No abstract available for this presentation
-
+
OA12 - Novel Therapies in MET, RET and BRAF
- Type: Oral Abstract Session
- Track: Targeted Therapy
- Presentations: 8
- Coordinates: 9/25/2018, 15:15 - 16:45, Room 106
-
+
OA12.01 - Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14-Skipping Mutations
15:15 - 15:25 | Presenter: Enriqueta Felip
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA12.02 - Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
15:25 - 15:35 | Presenter: Alexander Drilon
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA12.03 - Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.
15:35 - 15:45 | Presenter: Denis Moro-Sibilot
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA12.04 - Discussant - OA 12.01, OA 12.02, OA 12.03
15:45 - 16:00 | Presenter: Mark M. Awad
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA12.05 - Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial.
16:00 - 16:10 | Presenter: Julien Mazieres
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA12.06 - Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure
16:10 - 16:20 | Presenter: Anastasios Dimou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA12.07 - Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer
16:20 - 16:30 | Presenter: Geoffrey R. Oxnard
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA12.08 - Discussant - OA 12.05, OA 12.06, OA 12.07
16:30 - 16:45 | Presenter: Thomas Newsom-Davis
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.01 - Advanced NSCLC (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 132
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.01-01 - The Impact of Anlotinib on Brain Metastases of NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)
16:45 - 18:00 | Presenter: Wenhua Liang
- Abstract
Loading... -
+
P2.01-02 - Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study
16:45 - 18:00 | Presenter: Nir Peled
- Abstract
Loading... -
+
P2.01-03 - Quality of Life Outcomes for FDA-Approved Agents in Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Hamzeh Albaba
- Abstract
Loading... -
+
P2.01-04 - Reducing Time to Molecular Diagnosis for Advanced NSCLC in the Context of a Reference Testing Center
16:45 - 18:00 | Presenter: Alla'a Ali
- Abstract
Loading... -
+
P2.01-05 - Adenocarcinoma of the Lung: The Woman’s Cancer?
16:45 - 18:00 | Presenter: Noor Asaad Alsaadoun
- Abstract
Loading... -
+
P2.01-06 - HSP72 Expression Associates with Survival in EGFR Mutated NSCLC
16:45 - 18:00 | Presenter: Idoroenyi Amanam
- Abstract
Loading... -
+
P2.01-07 - Safety and Efficacy of LATTICE Radiotherapy in Voluminous Non-Small Cell Lung Cancer: A Retrospective Study of 10 Patients Over 7 Year Period
16:45 - 18:00 | Author(s): Beatriz E Amendola
- Abstract
Loading... -
+
P2.01-08 - Conversion Surgery for Locally Advanced Lung Adenocarcinoma Harboring Driver Gene Mutation After TKI Followed by Cytotoxic Agent
16:45 - 18:00 | Presenter: Masaya Aoki
- Abstract
Loading... -
+
P2.01-09 - Targetable Genomic Alterations in KRAS Mutant Lung Adenocarcinoma by Targeted Next Generation Sequencing
16:45 - 18:00 | Presenter: Edurne Arriola
- Abstract
Loading... -
+
P2.01-10 - Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: So Hyeon Bak
- Abstract
Loading... -
+
P2.01-11 - Characteristics of Non-Small Cell Lung Cancer: Differences by Sex and Hormonal Status in a Hispanic Population
16:45 - 18:00 | Author(s): Vianey Rodriguez-Lara
- Abstract
Loading... -
+
P2.01-12 - Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Marta Batus
- Abstract
Loading... -
+
P2.01-13 - Number, Rather Than Location of Metastases, Dictates Outcome in Stage IV, M1b, Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Amanda Jane Williams Gibson
- Abstract
Loading... -
+
P2.01-14 - Preferred and Achieved Goals of Patients with Metastatic Lung Cancer and Their Oncologists in End-of-Life Therapy
16:45 - 18:00 | Presenter: Annemarie Becker
- Abstract
Loading... -
+
P2.01-15 - A Radiologist-Led Training Workshop for MR Based Normal Tissue and Tumour Delineation for Lung Cancer Radiotherapy.
16:45 - 18:00 | Presenter: Sean Brown
- Abstract
Loading... -
+
P2.01-16 - Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients
16:45 - 18:00 | Presenter: Jianhua Chang
- Abstract
Loading... -
+
P2.01-17 - MALAT1-Mir-101-SOX9 Feedback Loop Modulates the Chemo-Resistance of Lung Cancer Cell to DDP via Wnt Signaling Pathway
16:45 - 18:00 | Presenter: Wei Chen
- Abstract
Loading... -
+
P2.01-18 - Differential Molecular Mechanisms Associated with Dramatic and Gradual Progression in NSCLC Patients with Intrathoracic Dissemination
16:45 - 18:00 | Presenter: Ying Chen
- Abstract
Loading... -
+
P2.01-19 - Radiomics Features of Contrast Enhanced CT as Prognostic Factors in Resectable Adenocarcinoma of Lung
16:45 - 18:00 | Presenter: Jooae Choe
- Abstract
Loading... -
+
P2.01-20 - FLT-PET for Detection of Relapse Following Radiotherapy for Lung Cancer. Preliminary Results
16:45 - 18:00 | Presenter: Tine Nøhr Christensen
- Abstract
Loading... -
+
P2.01-21 - Antigen Cascade Triggering Correlates with Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade with Nivolumab.
16:45 - 18:00 | Presenter: PIERPAOLO Correale
- Abstract
Loading... -
+
P2.01-22 - Increased Incidence, Morbidity and Mortality Rates for Lung Cancer in Women in Brazil Between 2000 and 2014
16:45 - 18:00 | Presenter: Guilherme Jorge Costa
- Abstract
Loading... -
+
P2.01-23 - Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Mathilde Couetoux Du Tertre
- Abstract
Loading... -
+
P2.01-24 - MLPH Activates CDC42/PAK1 Signaling to Promote Epithelial–Mesenchymal Transition via TGF-β in Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Chunhua Wei
- Abstract
Loading... -
+
P2.01-25 - MicroRNA-330-3p Promotes Brain Metastasis of Non-Small Cell Lung Cancer by Activating MAPK/MEK/ERK Signaling Through GRIA3
16:45 - 18:00 | Author(s): Chunhua Wei
- Abstract
Loading... -
+
P2.01-26 - Association of Base Excision Repair Gene Polymorphisms with Response to Chemotherapy of Advanced Non Small-Cell Lung Cancer
16:45 - 18:00 | Author(s): Jie Dong
- Abstract
Loading... -
+
P2.01-27 - MR, CT and Cone-Beam CT for Lymph Node Visualisation in Locally-Advanced Lung Cancer
16:45 - 18:00 | Author(s): Michael Dubec
- Abstract
Loading... -
+
P2.01-28 - Gender and Systemic Treatment Patterns: Impacts on the Overall Survival of Stage IV NSCLC 2010 – 2014 Diagnoses
16:45 - 18:00 | Presenter: Anifat A. Elegbede
- Abstract
Loading... -
+
P2.01-29 - Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Doreen Anuli Ezeife
- Abstract
Loading... -
+
P2.01-30 - Applicability of Lung-molGPA Index in Non-Small Cell Lung Cancer Patients with Different Gene Alterations and Brain Metastases
16:45 - 18:00 | Author(s): Kaiyan Chen
- Abstract
Loading... -
+
P2.01-31 - Updated EGFR Mutation Frequency in 1,689 NSCLC Brazilian Patients – A National-Wide Study
16:45 - 18:00 | Presenter: Carlos Gil Ferreira
- Abstract
Loading... -
+
P2.01-32 - Economic Evaluation of Diagnostic Platforms for T790M Detection in Post EGFR-TKI NSCLC in Brazil
16:45 - 18:00 | Presenter: Carlos Gil Ferreira
- Abstract
Loading... -
+
P2.01-33 - Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1 Containing Therapy (HUDSON)
16:45 - 18:00 | Presenter: Patrick M Forde
- Abstract
Loading... -
+
P2.01-34 - Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated with Immunotherapy and Ramucirumab Plus Docetaxel.
16:45 - 18:00 | Author(s): Ibtihaj Fughhi
- Abstract
Loading... -
+
P2.01-35 - Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Patients with Advanced Lung Cancer
16:45 - 18:00 | Presenter: Apar Kishor Ganti
- Abstract
Loading... -
+
P2.01-36 - Real-World Treatment Patterns in Treatment-Naïve Advanced NSCLC Patients in North America: A Systematic Literature Review
16:45 - 18:00 | Author(s): Aleksandra Gara
- Abstract
Loading... -
+
P2.01-37 - A Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) with Docetaxel in pts with Previously Treated NSCLC
16:45 - 18:00 | Author(s): Sawsan Rashdan
- Abstract
Loading... -
+
P2.01-38 - Sarcopenia is Associated with Metastatic Burden and is a Negative Prognostic Factor in Metastatic Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Chad Glisch
- Abstract
Loading... -
+
P2.01-39 - Can Benefit or Futility in Treating Advanced Nsclc Be Determined Early Using the LCSS 3-Item Global Index (3-IGI) PRO?
16:45 - 18:00 | Presenter: Richard J Gralla
- Abstract
Loading... -
+
P2.01-40 - Prognostic Importance of Sarcopeni and Inflammatory Statements in Stage III Non Small Cell Lung Carcinoma
16:45 - 18:00 | Author(s): Esra Gümüştepe
- Abstract
Loading... -
+
P2.01-41 - The Role and Mechanism Of FBW7 Deficiency in Advanced Non-Small Cell Lung Cancer with Docetaxel Resistance
16:45 - 18:00 | Author(s): Honglu Liang
- Abstract
Loading... -
+
P2.01-42 - Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy
16:45 - 18:00 | Presenter: Martin Gutierrez
- Abstract
Loading... -
+
P2.01-43 - ADSCaN: A Randomised Phase II Study of Accelerated, Dose Escalated, Sequential Chemo-Radiotherapy in Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Author(s): Claire Lawless
- Abstract
Loading... -
+
P2.01-44 - Prognostic Value of TP53 Hot Exon Mutation in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Yong He
- Abstract
Loading... -
+
P2.01-45 - Mutational and Inflammatory Biomarkers for Lung Cancer Patients with Pleural Effusions
16:45 - 18:00 | Presenter: Balazs Hegedus
- Abstract
Loading... -
+
P2.01-46 - Investigating the Effects of Prior Malignancy on NSCLC Trial Eligibility
16:45 - 18:00 | Presenter: Michael Herman
- Abstract
Loading... -
+
P2.01-47 - Clinical Outcome After Surgical Resection Of Clinical Single-station N2 Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Kwanyong Hyun
- Abstract
Loading... -
+
P2.01-48 - Predictive Factors in NSCLC Patients with Stage IIIB/IV Treated with First Line Platinum-Doublet Chemotherapy
16:45 - 18:00 | Presenter: Sofi Isaksson
- Abstract
Loading... -
+
P2.01-49 - Comparision of Radiotheraphy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Nadiye Akdeniz
- Abstract
Loading... -
+
P2.01-50 - Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Malinda Itchins
- Abstract
Loading... -
+
P2.01-51 - Study of CD26/DPP4 Expression in a Large Series of Non-Small Cell Lung Cancer Patients
16:45 - 18:00 | Author(s): Jae-Hwi Jang
- Abstract
Loading... -
+
P2.01-52 - Identification of Leptomeningeal Metastasis-Specific Exosomal miRNA Signatures in Cerebrospinal Fluids of NSCLC Patients
16:45 - 18:00 | Author(s): Ben-Yuan Jiang
- Abstract
Loading... -
+
P2.01-53 - Local Treatment for Oligoprogression/Oligometastases After Failure to Crizotinib for ALK-Rearranged Stage IV Lung Cancer
16:45 - 18:00 | Presenter: Tsz Yeung Kam
- Abstract
Loading... -
+
P2.01-54 - Predictive Factors for Thromboembolism in Advanced Lung Cancer Patients on Platinum Chemotherapy: A Prospective Study
16:45 - 18:00 | Presenter: Shruti Kate
- Abstract
Loading... -
+
P2.01-55 - Dual-Energy CT Scan to Evaluate Sarcopenia in Lung Cancer in Comparison with Conventional CT Scan
16:45 - 18:00 | Presenter: Eun Young Kim
- Abstract
Loading... -
+
P2.01-56 - Metastases in Residual PET Uptake of Lymph Nodes After Treatment: Added Value of CT Radiomic Approach for Prediction
16:45 - 18:00 | Presenter: Chu Hyun Kim
- Abstract
Loading... -
+
P2.01-57 - Prognostic Implication of Clinical, Imaging, and Pathologic Parameters in N2(+) Stage IIIA Lung Cancer Patients
16:45 - 18:00 | Author(s): Hakyoung Kim
- Abstract
Loading... -
+
P2.01-58 - Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort
16:45 - 18:00 | Presenter: Alyssa B Klein
- Abstract
Loading... -
+
P2.01-59 - The Cost of Lung Cancer in the County of Gävleborg – Sweden
16:45 - 18:00 | Presenter: Hirsh Koyi
- Abstract
Loading... -
+
P2.01-60 - Clinical Utility of Circulating Tumor Cell (CTC) Analysis Using Target Selector™ in Metastatic NSCLC Chemotherapy Patients
16:45 - 18:00 | Presenter: Lara Kujtan
- Abstract
Loading... -
+
P2.01-61 - Body Mass Index over Time is Associated with Overall Survival in Advanced NSCLC Patients Treated with Immunotherapy.
16:45 - 18:00 | Presenter: Stephanie Labomascus
- Abstract
Loading... -
+
P2.01-62 - Extracellular Vesicle-Based Egfr Genotyping in Bronchoalveolar Lavage Fluid from Non-Small Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Jong Sik Lee
- Abstract
Loading... -
+
P2.01-63 - Are Heart Doses Associated with Survival in NSCLC Treated with Post-Operative Radiotherapy? A National Population-Based Study
16:45 - 18:00 | Presenter: Chia Ching Lee
- Abstract
Loading... -
+
P2.01-64 - Prognostic Value of PET-CT after Induction Chemoradiotherapy and Curative Surgery in IIIA-N2 NSCLC: A Multi-Institutional Analysis
16:45 - 18:00 | Presenter: Jong Hoon Lee
- Abstract
Loading... -
+
P2.01-65 - Assessment of Individual and Combined of Five Serum Tumor Markers for Lung Cancer
16:45 - 18:00 | Presenter: Yuping Li
- Abstract
Loading... -
+
P2.01-66 - Comparison of EGFR Mutation Status in Tissue and Plasma Cell-Free DNA Detected by ARMS in Advanced Lung Adenocarcinoma Patients
16:45 - 18:00 | Presenter: Yuping Li
- Abstract
Loading... -
+
P2.01-67 - The Prognostic Analysis of Lung Cancer Patients with Occult Malignant Pleural Disease at Thoracotomy
16:45 - 18:00 | Presenter: Shaolei Li
- Abstract
Loading... -
+
P2.01-68 - Capture-Based Sequencing Depicts Evolution Characteristics of Pulmonary Sarcomatoid Carcinoma
16:45 - 18:00 | Presenter: Xuewen Liu
- Abstract
Loading... -
+
P2.01-69 - EZH2-Mediated Epigenetic Suppression Of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Xiyi Lu
- Abstract
Loading... -
+
P2.01-70 - Tumor Treating Fields and Radiosurgery for Supra- and/or Infratentorial Brain Metastases (1-10) from NSCLC in the Phase 3 METIS Study
16:45 - 18:00 | Author(s): Minesh P Mehta
- Abstract
Loading... -
+
P2.01-71 - Clinical Outcome of Induction Chemoradiotherapy Followed by Surgery for the Patients with cN2 Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Akihiro Miura
- Abstract
Loading... -
+
P2.01-72 - Bronchial Sleeve vs Pneumonectomy: Complications, Recurrences and Survival
16:45 - 18:00 | Author(s): Mario Montesinos Encalada
- Abstract
Loading... -
+
P2.01-73 - Automated Image Analysis Tool for Tumor Volume Growth Rate to Guide Precision Cancer Therapy: EGFR-Mutant NSCLC as a Paradigm
16:45 - 18:00 | Presenter: Mizuki Nishino
- Abstract
Loading... -
+
P2.01-74 - Docetaxel-Related Febrile Neutropenia (FN) And Patient Reported Symptoms/ QOL (PROs) in East Asian (EA) and Non-EA Patients
16:45 - 18:00 | Author(s): Yukie Omori
- Abstract
Loading... -
+
P2.01-75 - Study of Molecular Alterations in Cytological Smears By FISH In Patients with Advanced Non Small Cell Lung Carcinoma (NSCLC).
16:45 - 18:00 | Presenter: Julieta Belén Pandolfi
- Abstract
Loading... -
+
P2.01-76 - The Impact of Concordance with a Lung Cancer Diagnosis Pathway Guideline on Treatment Access in Patients with Stage IV Lung Cancer
16:45 - 18:00 | Author(s): Andrew Pattison
- Abstract
Loading... -
+
P2.01-77 - Interconversion of Two Commonly Used Performance Tools: An Analysis of 5844 Paired Assessments in 1501 Lung Cancer Patients
16:45 - 18:00 | Presenter: Kuruswamy Thurai Prasad
- Abstract
Loading... -
+
P2.01-78 - Validation of InVisionFirst ctDNA NGS Profiling via ddPCR Testing in Patients with Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Michael A. Pritchett
- Abstract
Loading... -
+
P2.01-79 - Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Matthew Ramotar
- Abstract
Loading... -
+
P2.01-80 - Performance Status and Resource Utilization in Patients Receiving Palliaitve Care with Stage IV Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Joshua Robert Rayburn
- Abstract
Loading... -
+
P2.01-81 - Treatment of Superior Sulcus Tumor: A Twelve-Year Single-Center Experience
16:45 - 18:00 | Presenter: Witold Rzyman
- Abstract
Loading... -
+
P2.01-82 - Neutrophil-to-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors
16:45 - 18:00 | Presenter: Diana Saravia
- Abstract
Loading... -
+
P2.01-83 - Evaluation of Dynamic Thiol/Disulphide Homeostasis in Advance Non-Small Cell Lung Cancer and Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Mutlu Hizal
- Abstract
Loading... -
+
P2.01-84 - Patterns of Central Nervous System Metastases in EGFR Mutated or ALK Rearranged Non Small Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Mansi Sharma
- Abstract
Loading... -
+
P2.01-85 - The Efficacy of the Traditional Chinese Medicine as Maintenance Therapy for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
16:45 - 18:00 | Presenter: Peng Shen
- Abstract
Loading... -
+
P2.01-86 - Genetic Profiling of Circulating Cell-Free DNA from Cerebrospinal Fluid and Plasma in ALK-Positive Lung Cancer with Brain Metastases
16:45 - 18:00 | Presenter: Liang Shi
- Abstract
Loading... -
+
P2.01-87 - Profiling the Symptom Burden of Patients with Metastatic NSCLC Receiving Either Chemotherapy or Targeted Therapy: Real-World Data
16:45 - 18:00 | Presenter: Qiuling Shi
- Abstract
Loading... -
+
P2.01-88 - C-Reactive Protein (CRP) as a Predictive Marker for Survival in Patients with Advanced NSCLC Treated with First Line Pembrolizumab Monotherapy
16:45 - 18:00 | Presenter: Yuji Shibata
- Abstract
Loading... -
+
P2.01-89 - Synergistic Cytotoxicity Through MAPK/ERK Pathway and ALK Inhibition in Crizotinib Resistant EML4-ALK-Positive Lung Cancer
16:45 - 18:00 | Presenter: Nensi Shrestha
- Abstract
Loading... -
+
P2.01-90 - PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small Cell Lung Cancer Patients with or without EGFR Mutation
16:45 - 18:00 | Presenter: Teerada Siripoon
- Abstract
Loading... -
+
P2.01-91 - Treatment Patterns in Patients with Stage IIIB-IV NSCLC in Clinical Practice: Retrospective Analysis of a UK Trust Database
16:45 - 18:00 | Presenter: Michael Snee
- Abstract
Loading... -
+
P2.01-92 - “All-In-One” Window: A New Way of Looking at Chest CT Studies in Thoracic Oncology
16:45 - 18:00 | Presenter: Annemie Snoeckx
- Abstract
Loading... -
+
P2.01-93 - The Analysis of the Soluble Programmed Death-1 of Lung Cancer Patients with Different Characteristics
16:45 - 18:00 | Author(s): Haibo Zhu
- Abstract
Loading... -
+
P2.01-94 - Diagnostic Patterns of Non-Small Cell Lung Cancer at Princess Margaret Cancer Centre
16:45 - 18:00 | Presenter: Mike Sung
- Abstract
Loading... -
+
P2.01-95 - Assesment the Fitness for Chemotherapy of NSCLC Patients using 6MWT
16:45 - 18:00 | Presenter: Zsuzsanna Szalai
- Abstract
Loading... -
+
P2.01-96 - Dysgeusia Associated with Nutritional and Quality of Life Parameters in Non-Small Cell Lung Cancer Patients Naïve to Chemotherapy
16:45 - 18:00 | Presenter: Jenny G. Turcott
- Abstract
Loading... -
+
P2.01-97 - Prognostic Factors in Resected Lung Mucinous Adenocarcinoma: Clinical and Pathological Features
16:45 - 18:00 | Presenter: Daisuke Ueda
- Abstract
Loading... -
+
P2.01-98 - Single-Isocenter Volumetric-Modulated Arc Radiosurgery for Non-Small-Cell Lung Cancer Patients with Multiple Brain Metastases
16:45 - 18:00 | Presenter: Megumi Uto
- Abstract
Loading... -
+
P2.01-99 - Can NGS NSCLC Testing Be Implemented Without in House Expertise? Clinical Utility of the First FDA-Approved Lung Cancer NGS End-To-End Solution
16:45 - 18:00 | Author(s): Sherrol McDonough
- Abstract
Loading... -
+
P2.01-100 - Different Genetic Mutations Enriched in Circulating Tumor DNA Predict Different Metastatic Sites in Lung Adenocarcinoma Patients
16:45 - 18:00 | Presenter: Liyun Miao
- Abstract
Loading... -
+
P2.01-101 - Dynamic Monitoring of Gene Alterations with ctDNA by NGS for EGFR Mutated Lung Adenocarcinoma Treated with Gefitinib in BENEFIT Study (CTONG 1405)
16:45 - 18:00 | Author(s): Jian-Chun Duan
- Abstract
Loading... -
+
P2.01-102 - Comprehensive Next-Generation Sequencing Guided Targeted Therapies Improve Clinical Outcomes of Lung Cancer Patients
16:45 - 18:00 | Presenter: Zhaoxia Wang
- Abstract
Loading... -
+
P2.01-103 - Neutrophil-to-Lymphocyte Ratio as a Predictor of Immunotherapy Treatment Outcomes in Advanced Non-Small Lung Cancer
16:45 - 18:00 | Presenter: Xiao Wang
- Abstract
Loading... -
+
P2.01-104 - Plasma T-Cell-Derived Circulating DNA in Advanced NSCLC is Not Correlated with TIL but has a Potential of Prognostic Value
16:45 - 18:00 | Author(s): Bowon Weerasubpong
- Abstract
Loading... -
+
P2.01-105 - Tumor Treating Fields Plus Standard of Care for Non-Small Cell Lung Cancer Following Platinum Failure: Phase 3 LUNAR Study
16:45 - 18:00 | Presenter: Uri Weinberg
- Abstract
Loading... -
+
P2.01-106 - A Comparative Analysis of Genomic Alterations by Tumor Tissue and Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Go-un Woo
- Abstract
Loading... -
+
P2.01-107 - Analysis of Mutation Detection by ctDNA on the Basis of Metastatic Sites in Lung Adenocarcinoma Patients
16:45 - 18:00 | Presenter: Renhua Guo
- Abstract
Loading... -
+
P2.01-108 - Temporal Heterogeneity of Resistant Mutations in Sequential ALK TKI Treated Lung Cancer Revealed by NGS-Based Liquid Biopsy
16:45 - 18:00 | Presenter: Yu Yang
- Abstract
Loading... -
+
P2.01-109 - Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC
16:45 - 18:00 | Presenter: Guangjian Yang
- Abstract
Loading... -
+
P2.01-110 - Unique Genomic Profile Revealed by Malignant Pleural Effusion
16:45 - 18:00 | Presenter: Zhihua Guo
- Abstract
Loading... -
+
P2.01-111 - Clinical Features and Prognosis of Eighty-Five Patients with Primary Pulmonary Lymphoepithelioma-Like Carcinoma
16:45 - 18:00 | Presenter: Qin Yin Yin
- Abstract
Loading... -
+
P2.01-112 - Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients with Lung Cancer Treated with Nivolumab
16:45 - 18:00 | Author(s): Eisuke Shibata
- Abstract
Loading... -
+
P2.01-113 - Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Luo-Sheng Yong
- Abstract
Loading... -
+
P2.01-114 - The Correlation Among PD-L1 Expression, TMB and Lung Immune Prognostic Index in Chinese Patients with Advanced Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Pei Yuan
- Abstract
Loading... -
+
P2.01-115 - Evaluation of EGFR T790M of Cell Free Circulating DNA in Plasma by Droplet Digital PCR for Progressive Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Zhihong Zhang
- Abstract
Loading... -
+
P2.01-116 - The Potential of Assessing Blood Tumor Mutation Burden (bTMB) Using a Large Panel
16:45 - 18:00 | Presenter: Kai Zhang
- Abstract
Loading... -
+
P2.01-117 - Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Jun Zhao
- Abstract
Loading... -
+
P2.01-118 - LINE-1 Retrotransposition Promotes the Occurrence and Progression of Lung Squamous Cell Carcinoma
16:45 - 18:00 | Author(s): Rui Zhang
- Abstract
Loading... -
+
P2.01-119 - Phase III Randomized Trial of Palonosetron and Dexamethasone with Aprepitant to Prevent Full Dose Single-Day Cisplatin-Based CINV in Lung Cancer
16:45 - 18:00 | Presenter: Yongchang Zhang
- Abstract
Loading... -
+
P2.01-120 - First Study to Evaluate the Efficacy of SB Oral Solution to Prevent Neutropenia and FN Induced by Platinum-Based Chemotherapy in Lung Cancer
16:45 - 18:00 | Presenter: Yongchang Zhang
- Abstract
Loading... -
+
P2.01-121 - Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma
16:45 - 18:00 | Presenter: Chengzhi Zhou
- Abstract
Loading... -
+
P2.01-122 - Individual Precision Surgery for Locally Advanced Non-small Cell Lung Cancer Based on Molecular Staging and Typing : The Chinese Experience.
16:45 - 18:00 | Presenter: Qinghua Zhou
- Abstract
Loading... -
+
P2.01-123 - Translational Medicine of Lung Cancer Metastasis: From Bench to Bedside
16:45 - 18:00 | Presenter: Qinghua Zhou
- Abstract
Loading... -
+
P2.01-124 - SIB-IMRT in Symptomatic Brain Metastases for NSCLC: A Randomized Controlled Study of WBRT Comparing 25Gy and 30Gy
16:45 - 18:00 | Presenter: Jian Zhu
- Abstract
Loading... -
+
P2.01-125 - EGFR Mutations by NGS in Advanced Squamous Cell Lung Cancer
16:45 - 18:00 | Presenter: Govind Babu K
- Abstract
Loading... -
+
P2.01-126 - MicroRNA-330-3p Modulates Tumor Vascular Normalization After Hypofractionated Radiotherapy by Targeting p-STAT3/ HIF-1 Alpha Pathway
16:45 - 18:00 | Author(s): Xiong Chun Jin
- Abstract
Loading... -
+
P2.01-127 - Efficacy of Endostar Combined with Whole Brain Radiotherapy in Patients with NSCLC Brain Metastases
16:45 - 18:00 | Author(s): Lingjuan Chen
- Abstract
Loading... -
+
P2.01-128 - Low Positivity Rate in T790M Detection with ctDNA in NSCLC and Post EGFR-TKI Progression – Timing or Sensitivity?
16:45 - 18:00 | Presenter: Carlos Gil Ferreira
- Abstract
Loading... -
+
P2.01-129 - Potential Impact of KRAS Molecular Profiling of Non-Squamous Non-Small Cell Lung Cancer (NSCLC).
16:45 - 18:00 | Presenter: Nagla Abdel Karim
- Abstract
Loading... -
+
P2.01-130 - Detection of Actionable Mutation Status in Advanced Non-Small Cell Lung Cancer by Next-Generation Sequencing of Circulating Tumor DNA
16:45 - 18:00 | Author(s): YanLi Yang
- Abstract
Loading... -
+
P2.01-131 - Apatinib as an Alternative for Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Zhuolin Wu
- Abstract
Loading... -
+
P2.01-132 - Comparison Molecular Profiles in NSCLC by Using Different NGS Platforms and
Different Variant Frequency Cutoff16:45 - 18:00 | Author(s): Somthawin Lukrak
- Abstract
Loading...
-
+
P2.03 - Biology (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 37
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.03-01 - Prevalence of EGFR Alterations in Chilean Lung Cancer Patients: A Retrospective Study
16:45 - 18:00 | Author(s): Roger Gejman
- Abstract
Loading... -
+
P2.03-02 - Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP)
16:45 - 18:00 | Presenter: Ramon Palmero
- Abstract
Loading... -
+
P2.03-03 - Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective
16:45 - 18:00 | Author(s): Tracy Stockley
- Abstract
Loading... -
+
P2.03-04 - Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience
16:45 - 18:00 | Author(s): Tracy Stockley
- Abstract
Loading... -
+
P2.03-05 - Biologic Profiling of Brain Metastasis from Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Tomohito Saito
- Abstract
Loading... -
+
P2.03-06 - Serum Syndechan-1 Levels in Patients with Nonsmall Cell Lung Cancer
16:45 - 18:00 | Presenter: Ibrahim Tek
- Abstract
Loading... -
+
P2.03-07 - Radiomic Signatures Linked to Genetic Alterations as Detected by Next-Generation Sequencing: A Radiogenomics Analysis of Early-Stage NSCLC
16:45 - 18:00 | Presenter: Sibo Tian
- Abstract
Loading... -
+
P2.03-08 - Molecular Spectrum of Patients with MSH2 Mutations in Chinese Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Wenxian Wang
- Abstract
Loading... -
+
P2.03-09 - The Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study
16:45 - 18:00 | Author(s): Wenxian Wang
- Abstract
Loading... -
+
P2.03-10 - Gene Mutational Profiling Of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS
16:45 - 18:00 | Presenter: Chunwei Xu
- Abstract
Loading... -
+
P2.03-11 - PDGFRA Defines a Unique Molecular Subtypes of Chinese Non-Small Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Chunwei Xu
- Abstract
Loading... -
+
P2.03-12 - EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer
16:45 - 18:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P2.03-13 - SWATH MS Analysis of Serine Hydrolase Activity in Human Lung Adenocarcinoma for Biomarker Discovery
16:45 - 18:00 | Author(s): Tatjana Sajic
- Abstract
Loading... -
+
P2.03-14 - PKCι-PAK1 Pathway Modulates Sensitivity to Therapy in EGFR, KRAS Mutant and Squamous Cell Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Masaoki Ito
- Abstract
Loading... -
+
P2.03-15 - Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC
16:45 - 18:00 | Presenter: Niki Karachaliou
- Abstract
Loading... -
+
P2.03-16 - TGF-β Induced EMT and Stemness Characteristics are Associated with Epigenetic Regulation in Lung Cancer
16:45 - 18:00 | Presenter: Seung Joon Kim
- Abstract
Loading... -
+
P2.03-17 - EGFR T790M Mutation may not be Generated through Selection by EGFR-TKI from Randomly Occurring Mutations in Vitro Using ENU
16:45 - 18:00 | Presenter: Yoshihisa Kobayashi
- Abstract
Loading... -
+
P2.03-18 - X-Inactivation Specific Transcript (XIST)-Mediated miRNA Sequestration In NSCLC
16:45 - 18:00 | Presenter: Erin A Marshall
- Abstract
Loading... -
+
P2.03-19 - RET-Mediated Activation of Ezrin is Associated with Cell Motility and Survival in a Subset of Lung Adenocarcinomas
16:45 - 18:00 | Presenter: Serisha Moodley
- Abstract
Loading... -
+
P2.03-20 - Factor XIIIA-Expressing Inflammatory Monocytes Promote Lung Squamous Cancer through Fibrin Cross-Linking
16:45 - 18:00 | Presenter: Chad Victor Pecot
- Abstract
Loading... -
+
P2.03-21 - Mechanistic Investigation of DRD1 in Lung Cancer
16:45 - 18:00 | Presenter: Leila Toulabi
- Abstract
Loading... -
+
P2.03-22 - OCT4&SOX2 Specific CTLs Plus PD-1 Inhibitor Had Synergistic Effect on Killing CSC And Treating Drug-Resistant Lung Cancer Mice
16:45 - 18:00 | Author(s): Xueyan Zhang
- Abstract
Loading... -
+
P2.03-23 - MicroRNA-30e Inhibits Cell Proliferation and Invasion in Non-Small Cell Lung Cancer via Directly Targeting SOX9
16:45 - 18:00 | Presenter: Lei Zhao
- Abstract
Loading... -
+
P2.03-24 - CD90 Enhances Metastasis by Epithelial-Mesenchymal Transdifferentiation in Lung Adenocacinoma
16:45 - 18:00 | Author(s): Liu Pan
- Abstract
Loading... -
+
P2.03-25 - Loss of Expression Rather Than Cytoplasmic Mislocalization of RUNX3 Predicts Worse Outcome in Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Xiaohui Chen
- Abstract
Loading... -
+
P2.03-26 - A Prospective Cohort Study of TMB and Determinants of ctDNA Detection by Comprehensive Genomic Profiling in Stage I Lung Adenocarcinomas
16:45 - 18:00 | Presenter: Kezhong Chen
- Abstract
Loading... -
+
P2.03-27 - Polymorphisms in Folate Metabolism Related Genes Affect the Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Sun ha Choi
- Abstract
Loading... -
+
P2.03-28 - Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer
16:45 - 18:00 | Author(s): Francesco Grossi
- Abstract
Loading... -
+
P2.03-29 - Prognostic Significance of Phosphorylated Fyn in Patients with Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Shigeto Nishikawa
- Abstract
Loading... -
+
P2.03-30 - Proteins Involved in Necroptosis and DNA Damage Repair and Survival of Stage I Non-Small-Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Jeong-Seon Ryu
- Abstract
Loading... -
+
P2.03-31 - LncRNA RGMB-AS1 Affects Lung Adenocarcinoma Prognosis by Regulating Microtube Associated Genes: A Genome-Wide Analysis in Silicon
16:45 - 18:00 | Presenter: Xiaoshun Shi
- Abstract
Loading... -
+
P2.03-32 - Genome-Wide Analysis of m6A-Modified RNA Binding Proteins Associated with Lung Cancer Survival
16:45 - 18:00 | Presenter: Xiaoshun Shi
- Abstract
Loading... -
+
P2.03-33 - Anti-Aging Gene, Klotho is a Predictive Factor of Pemetrexed for Lung Cancer Treatment
16:45 - 18:00 | Presenter: Kyoshiro Takegahara
- Abstract
Loading... -
+
P2.03-34 - The Relationship Between Treatment Response and Serum EGFR Level in Nonsmall Cell Lung Cancer
16:45 - 18:00 | Presenter: Ibrahim Tek
- Abstract
Loading... -
+
P2.03-35 - Non-Small-Cell Lung Cancer with SMO Gene Variants of Uncertain Significance Share Distinct Molecular Features
16:45 - 18:00 | Author(s): Wenxian Wang
- Abstract
Loading... -
+
P2.03-36 - DNA Methylation: A More Sensitive Marker for Treatment Monitoring?
16:45 - 18:00 | Author(s): Shu Xia
- Abstract
Loading... -
+
P2.03-37 - The Efficiency of Octamer-4 Specific Cytotoxic T Cells Induce By CD40-B Cells in Killing Lung Cancer Stem-Like Cells
16:45 - 18:00 | Author(s): Xueyan Zhang
- Abstract
Loading...
-
+
P2.04 - Immunooncology (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 30
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.04-01 - Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells.
16:45 - 18:00 | Author(s): Graciela Cruz-Rico
- Abstract
Loading... -
+
P2.04-02 - Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab
16:45 - 18:00 | Author(s): Giovanni Rossi
- Abstract
Loading... -
+
P2.04-03 - NF-κB and HIF-1α Play Important Roles in Regulating PD-L1 Expression by EGFR or KRAS Mutants in Non-Small Cell Lung Cancer Cells
16:45 - 18:00 | Author(s): Rong Guo
- Abstract
Loading... -
+
P2.04-04 - Expression of Intratumoral Programmed Cell Death-Ligand 1 (PD-L1) and Intratumoral CD4+T Cell, CD8+T Cell and FOXP3+T Cell in Lung Cancer
16:45 - 18:00 | Presenter: Yasuto Jin
- Abstract
Loading... -
+
P2.04-05 - Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.
16:45 - 18:00 | Author(s): Tomasz Kucharczyk
- Abstract
Loading... -
+
P2.04-06 - Increased Plasma Cell % and Decreased B-Cells in Tumor Immune Infiltrates Are Associated with Worse Prognosis in Lung Adenocarcinomas
16:45 - 18:00 | Presenter: Hee Eun Lee
- Abstract
Loading... -
+
P2.04-07 - Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand-1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues
16:45 - 18:00 | Author(s): Wenyu Sun
- Abstract
Loading... -
+
P2.04-08 - Platinum-Based Chemotherapy is Associated with Altered PD-L1 Expression in Lung Cancer
16:45 - 18:00 | Presenter: Judit Moldvay
- Abstract
Loading... -
+
P2.04-09 - Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Marcelo Vailati Negrao
- Abstract
Loading... -
+
P2.04-10 - Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients
16:45 - 18:00 | Presenter: Francesco Passiglia
- Abstract
Loading... -
+
P2.04-11 - An IL-8/IFN-gammma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients with NSCLC
16:45 - 18:00 | Presenter: Francesco Passiglia
- Abstract
Loading... -
+
P2.04-12 - A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.
16:45 - 18:00 | Presenter: Sara Pilotto
- Abstract
Loading... -
+
P2.04-13 - The Immune Checkpoint, HVEM Contribute to Immune Escape in Non Small Cell Lung Cancer of Lacking PDL1 Expression
16:45 - 18:00 | Presenter: Shengxiang Ren
- Abstract
Loading... -
+
P2.04-14 - Tumor Mutational Burden Assessed by a Targeted NGS Assay Predicts Benefit from Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Sacha I Rothschild
- Abstract
Loading... -
+
P2.04-15 - Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naïve Lesions
16:45 - 18:00 | Presenter: Kenichi Suda
- Abstract
Loading... -
+
P2.04-16 - Correlation Between Programmed Death Ligand 1(PD-L1) Expression and Solid Component on HRCT in Stage I Lung Cancer Patients
16:45 - 18:00 | Presenter: Ryosuke Tsugitomi
- Abstract
Loading... -
+
P2.04-17 - Pre-Therapy Radiomic Features Can Distinguish Hyperprogression from Other Response Patterns to PD1/PD-L1 Inhibitors in NSCLC
16:45 - 18:00 | Author(s): Pradnya Dinkar Patil
- Abstract
Loading... -
+
P2.04-18 - The Association Between IDO Activity and Clinical Prognosis in Patients with Non-Small Cell Lung Cancer After Radiotherapy
16:45 - 18:00 | Author(s): Yaoyao Zhu
- Abstract
Loading... -
+
P2.04-19 - Correlation of Clinicopathological Characteristics with Tumor Mutation Burden in Chinese Patients with NSCLC
16:45 - 18:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P2.04-20 - Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLC
16:45 - 18:00 | Presenter: Mehmet Altan
- Abstract
Loading... -
+
P2.04-21 - Real World Experience of Immune Checkpoint Inhibitors In NSCLC: Our First 10 Months Experience at Leeds Cancer Centre, UK
16:45 - 18:00 | Presenter: Kathryn Ellenger
- Abstract
Loading... -
+
P2.04-22 - Dendritic Cell Based Immunotherapy in Stage IIB-IIIA Non-Small Cell Lung Cancer Patients: 10-Years Experience.
16:45 - 18:00 | Presenter: Natalia Khranovska
- Abstract
Loading... -
+
P2.04-23 - Immune-Related Adverse Events: The Growing Pains of Immunooncology
16:45 - 18:00 | Presenter: Meghan J Mooradian
- Abstract
Loading... -
+
P2.04-24 - Nivolumab in the "Real World": Are the Results of Clinical Trials Reproducible?
16:45 - 18:00 | Presenter: Inmaculada Ramos García
- Abstract
Loading... -
+
P2.04-25 - Randomized Clinical Trial Comparing Immunotherapy Plus SABR (I-SABR) Versus SABR Alone for Early Stage NSCLC
16:45 - 18:00 | Presenter: Joe Y Chang
- Abstract
Loading... -
+
P2.04-26 - Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC
16:45 - 18:00 | Presenter: Grace K Dy
- Abstract
Loading... -
+
P2.04-27 - Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC
16:45 - 18:00 | Author(s): Carlos Arce-Lara
- Abstract
Loading... -
+
P2.04-28 - Use of Immune Checkpoint Inhibitors (ICIs) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (PS)
16:45 - 18:00 | Presenter: Jonathan R Thompson
- Abstract
Loading... -
+
P2.04-29 - Preliminary Results With Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P2.04-30 - PD-1/PD-L1 Inhibition Might be an Option for the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma
16:45 - 18:00 | Author(s): Kai Yin
- Abstract
Loading...
-
+
P2.06 - Mesothelioma (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 41
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.06-01 - Short-Term Outcome of Entire Pleural Intensity-Modulated Radiotherapy in a Neoadjuvant Setting for Malignant Mesothelioma
16:45 - 18:00 | Presenter: Ji Hyun Hong
- Abstract
Loading... -
+
P2.06-02 - Feasibility of Intensity Modulated Radiotherapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma Patients
16:45 - 18:00 | Presenter: Oscar Arrieta
- Abstract
Loading... -
+
P2.06-03 - Can We Predict Pathological Nodal Positivity in Malignant Pleural Mesothelioma from Preoperative Clinical Variables?
16:45 - 18:00 | Presenter: Silviu I Buderi
- Abstract
Loading... -
+
P2.06-04 - Throughput of a Specialist Mesothelioma Multidisciplinary Team Meeting at a Radical Treatment Centre in the United Kingdom.
16:45 - 18:00 | Presenter: Edward J Caruana
- Abstract
Loading... -
+
P2.06-05 - TTFields Applied to the Torso and Upper Abdomen: Safety Meta-Analysis of 176 Patients from four Phase I-II Trials
16:45 - 18:00 | Presenter: Giovanni L Ceresoli
- Abstract
Loading... -
+
P2.06-06 - Role of GITRL-GITR System in Promoting Proliferation of Malignant Mesothelioma
16:45 - 18:00 | Presenter: Mei-Lin Chan
- Abstract
Loading... -
+
P2.06-07 - Genomic Deletion of BAP1 and CDKN2A are Better MM Diagnostic Biomarkers.
16:45 - 18:00 | Presenter: Yuen Yee Cheng
- Abstract
Loading... -
+
P2.06-08 - ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo
16:45 - 18:00 | Presenter: Puey Ling Chia
- Abstract
Loading... -
+
P2.06-09 - MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in pts with Malignant Mesothelioma
16:45 - 18:00 | Author(s): Matthew G Krebs
- Abstract
Loading... -
+
P2.06-10 - Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress
16:45 - 18:00 | Presenter: Nobukazu Fujimoto
- Abstract
Loading... -
+
P2.06-11 - A Phase I/II Study of Intrapleural Ad-SGE-REIC Administration in Patients with Refractory Malignant Pleural Mesothelioma
16:45 - 18:00 | Presenter: Yasushi Goto
- Abstract
Loading... -
+
P2.06-12 - Improving Quality of Care for Pleural Mesothelioma: 2018 National Mesothelioma Audit Results for England and Wales
16:45 - 18:00 | Presenter: Susan V Harden
- Abstract
Loading... -
+
P2.06-13 - Poor Nutritional Status Is a Poor Prognostic Factor in Malignant Pleural Mesothelioma
16:45 - 18:00 | Author(s): Masaki Hashimoto
- Abstract
Loading... -
+
P2.06-14 - Does Size Matter? A Population-Based Analysis of Malignant Pleural Mesothelioma
16:45 - 18:00 | Presenter: Jiaxi He
- Abstract
Loading... -
+
P2.06-15 - Malignant Pleural Mesothelioma in Young Adult People in Uganda
16:45 - 18:00 | Presenter: Nehemiya Igulu Bandese
- Abstract
Loading... -
+
P2.06-16 - YB-1: An Important Driver of Mesothelioma Drug Resistance and a Potential Novel Therapeutic Target
16:45 - 18:00 | Author(s): Thomas George Johnson
- Abstract
Loading... -
+
P2.06-17 - Real-World Accuracy of Malignant Pleural Mesothelioma (MPM) Preoperative Magnetic Resonance Imaging (MRI) for Staging the Diaphragm.
16:45 - 18:00 | Presenter: Sharyn Katz
- Abstract
Loading... -
+
P2.06-18 - Comparison of Extubation Time of Pleulectomy/Decortication with Lobectomy Under General Anesthesia Using Desflurane
16:45 - 18:00 | Presenter: Keisuke Kawata
- Abstract
Loading... -
+
P2.06-19 - Targeting Polyamines as Potential Adjuvant Therapy in Malignant Pleural Mesothelioma Xenograft Models
16:45 - 18:00 | Presenter: Sze Kwan Lam
- Abstract
Loading... -
+
P2.06-21 - Low Intratumoral Platinum Concentration is Associated with Unfavorable Clinical Outcome in Malignant Pleural Mesothelioma
16:45 - 18:00 | Presenter: Viktoria Laszlo
- Abstract
Loading... -
+
P2.06-22 - Proposal of a New Local Recurrence Score for Patients with Malignant Pleural Mesothelioma
16:45 - 18:00 | Author(s): Olivia Lauk
- Abstract
Loading... -
+
P2.06-23 - Association of Two BRM Promoter Polymorphisms and Tobacco Exposure with Malignant Pleural Mesothelioma (MPM) Risk and Survival
16:45 - 18:00 | Presenter: Min Joon Lee
- Abstract
Loading... -
+
P2.06-24 - The Impact of Demographic and Socioeconomic Factors on Survival of Patients with Mesothelioma in the USA
16:45 - 18:00 | Presenter: Rami Manochakian
- Abstract
Loading... -
+
P2.06-25 - Combined Immune Checkpoint Blockade in Malignant Pleural Mesothelioma: In Vivo Validation of in Vitro Results
16:45 - 18:00 | Author(s): Elly Marcq
- Abstract
Loading... -
+
P2.06-26 - Ribonucleotide Reductase Subunit M1 but not M2 is Associated to Better PFS in Patients with Advanced Stage Mesothelioma
16:45 - 18:00 | Presenter: Saé Muñiz-Hernández
- Abstract
Loading... -
+
P2.06-27 - Extrapleural Pneumonectomy, Radiation Therapy, and Chemotherapy for Epithelioid Malignant Pleural Mesothelioma
16:45 - 18:00 | Presenter: Kazunori Okabe
- Abstract
Loading... -
+
P2.06-28 - Assessment of Chest Wall Motion Using Structured Light Plethysmography (SLP) in Mesothelioma and Benign Pleural Disease
16:45 - 18:00 | Presenter: Nicola Oswald
- Abstract
Loading... -
+
P2.06-29 - Expression of Estrogen Receptor Beta (ERb) and its Prognostic Value in the Pleural Mesothelioma.
16:45 - 18:00 | Presenter: Jeronimo Rafael Rodriguez-Cid
- Abstract
Loading... -
+
P2.06-30 - Association of Histopathological Patterns of Mesothelioma and Response to Treatment with Chemotherapy
16:45 - 18:00 | Presenter: Jeronimo Rafael Rodriguez-Cid
- Abstract
Loading... -
+
P2.06-31 - Inhibition of Heat Shock Protein 70 Function Suppresses Proliferation in Mesothelioma Cells
16:45 - 18:00 | Presenter: Kosuke Sakai
- Abstract
Loading... -
+
P2.06-32 - YB-1 - A Key Factor in Mesothelioma Aggressive Growth and Behaviour
16:45 - 18:00 | Presenter: Karin Schelch
- Abstract
Loading... -
+
P2.06-33 - Heterogeneity in Care Pathways for Patients with Malignant Pleural Mesothelioma Presenting at a Quaternary Thoracic Oncology Center in Quebec
16:45 - 18:00 | Author(s): Rola Hamed
- Abstract
Loading... -
+
P2.06-34 - Inhibition of the HGF/c-Met Pathway for Malignant Mesothelioma with an Intra-Thoracic Injection of the NK4 Expressing Adenoviral Vectors
16:45 - 18:00 | Presenter: Yuji Tada
- Abstract
Loading... -
+
P2.06-35 - Pleurectomy Decortication Versus Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma: SPARCS Data
16:45 - 18:00 | Presenter: Maaike Van Gerwen
- Abstract
Loading... -
+
P2.06-36 - EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM
16:45 - 18:00 | Author(s): Jo Raskin
- Abstract
Loading... -
+
P2.06-37 - Four Immunohistochemical Assays to Measure the PD-L1 Expression in Malignant Pleural Mesothelioma
16:45 - 18:00 | Presenter: Takuya Watanabe
- Abstract
Loading... -
+
P2.06-38 - Mesothelioma Stem Cells May Be the Critical Factor of Treatment Failure
16:45 - 18:00 | Presenter: Licun Wu
- Abstract
Loading... -
+
P2.06-39 - Next Generation Sequencing Reveals Genetic Landscape of Malignant Mesothelioma
16:45 - 18:00 | Author(s): Jun Ren
- Abstract
Loading... -
+
P2.06-40 - VISTA is Highly Expressed in Malignant Pleural Mesothelioma (MPM) and Independent of PD-L1 Expression
16:45 - 18:00 | Presenter: Marjorie G. Zauderer
- Abstract
Loading... -
+
P2.06-41 - Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC
16:45 - 18:00 | Presenter: Yu Zhi Zhang
- Abstract
Loading... -
+
P2.06-42 - AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma.
16:45 - 18:00 | Presenter: Federica Zito Marino �
- Abstract
Loading...
-
+
P2.09 - Pathology (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 32
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.09-01 - Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma
16:45 - 18:00 | Presenter: Hui Yu
- Abstract
Loading... -
+
P2.09-02 - Comprehensive Assessment of PD-L1 Immunohistochemistry on Paired Tissue and Cytology Specimens in Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Andréanne Gagné
- Abstract
Loading... -
+
P2.09-03 - Rapid-Immunocytochemistry for Evaluation of Surgical Margin in Sublobar Pulmonary Resection
16:45 - 18:00 | Presenter: Nobuyasu Kurihara
- Abstract
Loading... -
+
P2.09-04 - PD-L1 Expression in Primary Lung Adenocarcinoma and its Relation with EGFR / KRAS Mutation and Clinicopathological Features
16:45 - 18:00 | Presenter: Lin Li
- Abstract
Loading... -
+
P2.09-05 - Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001
16:45 - 18:00 | Presenter: Aaron Lisberg
- Abstract
Loading... -
+
P2.09-06 - Expression of PD-L1 on Routine Non-Small Cell Lung Carcinoma Sections: Comparative Assessment of SP263 (Ventana) and 22C3 (DAKO pharmDx)
16:45 - 18:00 | Presenter: Anne Marie Quinn
- Abstract
Loading... -
+
P2.09-07 - Does Metastatic Site Matter for PD-L1 Testing in Stage IV NSCLC?
16:45 - 18:00 | Presenter: Hangjun Wang
- Abstract
Loading... -
+
P2.09-08 - Clinical Outcomes of Histology Versus Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Ying Wang
- Abstract
Loading... -
+
P2.09-09 - Precision and Repeatability of VENTANA DLL3 (SP347) Assay Immunohistochemistry Assay in Fine Needle Aspirations of Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Brittany Admire
- Abstract
Loading... -
+
P2.09-10 - qRT-PCR as an Efficient and Reliable Diagnostic Screening Approach for the Detection of EML4-ALK Fusion Gene in NSCLC Samples: A Pilot Study
16:45 - 18:00 | Presenter: Anuradha Choughule
- Abstract
Loading... -
+
P2.09-11 - TMB Estimated with Targeted NGS in Early Stage Squamous Cell Carcinoma: Correlation with PD-L1 Expression and Lymphocyte Density
16:45 - 18:00 | Presenter: Susana Hernandez
- Abstract
Loading... -
+
P2.09-12 - EGFR Mutation Status in Squamous Cell Carcinoma or Non-Small Cell Carcinoma Favor Squamous Cell Carcinoma Diagnosed from Small Lung Biopsies
16:45 - 18:00 | Presenter: Hsiang-Ling Ho
- Abstract
Loading... -
+
P2.09-13 - Correlation of ROS1 (SP384) Immunohistochemistry with ROS1 Rearrangement Determined by Fluorescence in Situ Hybridization
16:45 - 18:00 | Author(s): Richard S.P. Huang
- Abstract
Loading... -
+
P2.09-14 - The Detection of EGFR Gene Mutation from Washing Solution of Devices used for the Bronchoscopic Examination
16:45 - 18:00 | Presenter: Rie Nakahara
- Abstract
Loading... -
+
P2.09-15 - A Next Generation Sequencing (NGS) RNA-Scan Multiplex Panel (QIAseq) to Identify Gene-Rearranged Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Rebecca Y Tay
- Abstract
Loading... -
+
P2.09-16 - Heterogeneity Analyses of MSLCs——Especially in the EGFR Mutation-Positive Ones
16:45 - 18:00 | Presenter: Yinghui Xu
- Abstract
Loading... -
+
P2.09-17 - A Call to Action: Rapid Collection of Post-Mortem Lung Cancer Tissue in the Community to Enable Lung Cancer Research
16:45 - 18:00 | Presenter: Theresa A Boyle
- Abstract
Loading... -
+
P2.09-18 - A Clinicopathologic Analysis of Pulmonary Sclerosing Pneumocytoma in Korea : A Muticenter Study
16:45 - 18:00 | Author(s): Seung Yeon Ha
- Abstract
Loading... -
+
P2.09-19 - Utilising Heterogeneity: Using a Digital Database of Lung Cancers and Immune Profile to Complement Subjective Assessment
16:45 - 18:00 | Presenter: Alexander Haragan
- Abstract
Loading... -
+
P2.09-20 - Minor Components of Solid Pattern is a Significant Poor Prognostic Factor in Pathological Stage I Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Miao Huang
- Abstract
Loading... -
+
P2.09-21 - Women with Synchronous or Metachronous Lung and Ovarian Cancers: A Multi-Institutional Report
16:45 - 18:00 | Author(s): Annapaola Mariniello
- Abstract
Loading... -
+
P2.09-22 - Relevance of Results of Intraoperative Pleural Lavage Cytology and Histological Subtype in Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Masashi Mikubo
- Abstract
Loading... -
+
P2.09-23 - A Combination of Podoplanin and E-Cadherin Expression in Lung SqCC may be a Poor Prognostic Indicator: A Propensity Score-Matched Analysis.
16:45 - 18:00 | Presenter: Ryo Miyata
- Abstract
Loading... -
+
P2.09-24 - MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
16:45 - 18:00 | Author(s): Hui Yu
- Abstract
Loading... -
+
P2.09-25 - Abundant Tumor Promoting Stromal Cells in Lung Adenocarcinoma with Hypoxic Regions
16:45 - 18:00 | Presenter: Hiroshi Nakamura
- Abstract
Loading... -
+
P2.09-26 - Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Takashi Ohno
- Abstract
Loading... -
+
P2.09-27 - Prognostic Significance of Vascular Invasion in Pathological Stage IA Lung Adenocarcinoma According to the 8th Edition of the TNM Classification
16:45 - 18:00 | Presenter: Joji Samejima
- Abstract
Loading... -
+
P2.09-28 - Detection of Isolated Tumor Cells in Regional Lymph Nodes from pN0 Lung Cancer by Negative Selection Using Immunomagnetic Beads
16:45 - 18:00 | Presenter: Xizhao Sui
- Abstract
Loading... -
+
P2.09-29 - Automatic Lung Cancer Staging from Medical Reports Using Natural Language Processing
16:45 - 18:00 | Presenter: Xizhao Sui
- Abstract
Loading... -
+
P2.09-30 - Clinicopathological Investigation of Four Resected Cases for Pleomorphic Carcinoma of the Lung
16:45 - 18:00 | Presenter: Kenichi Taguchi
- Abstract
Loading... -
+
P2.09-31 - Cisplatinum Suppressed Metastasis of NSCLC by Inhibiting Macrophage M2-Like Polarization
16:45 - 18:00 | Presenter: Yanjun Xu
- Abstract
Loading... -
+
P2.09-32 - Detached Epithelial Cell Cluster Size in Lung Adenocarcinoma is a Marker of Poor Prognosis
16:45 - 18:00 | Presenter: Akihiko Yoshizawa
- Abstract
Loading...
-
+
P2.10 - Prevention and Tobacco Control (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 17
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.10-01 - Success of a Pharmacy-Driven Smoking Cessation Program
16:45 - 18:00 | Presenter: Catherine E Burdalski
- Abstract
Loading... -
+
P2.10-02 - Variations in Smoking Cessation Activities at Ontario’s Regional Cancer Centres
16:45 - 18:00 | Author(s): Naomi Schwartz
- Abstract
Loading... -
+
P2.10-03 - Feasibility and Acceptability of E-Cigarettes as an Aid to Quitting Smoking in Lung Cancer Patients: A Pilot Study
16:45 - 18:00 | Presenter: Stephen James Harrow
- Abstract
Loading... -
+
P2.10-04 - Pattern and Factors Associated with Intention to Quit Tobacco Use in a Rural Community of Anambra State of Nigeria
16:45 - 18:00 | Presenter: Uzochukwu Ofonakara
- Abstract
Loading... -
+
P2.10-05 - Provider Medical Specialty Influences Smoking Cessation Counseling at an Academic Medical Center and Veterans Affairs in U.S. Mid-South
16:45 - 18:00 | Presenter: Jennifer A. Lewis
- Abstract
Loading... -
+
P2.10-06 - The Risk of Lung Cancer Among Women Who Start Smoking As Teenagers
16:45 - 18:00 | Presenter: Malcolm Tagbarha
- Abstract
Loading... -
+
P2.10-07 - Health Professional’s Perception Towards Smoking: A Cross-Sectional Study from Bangalore, India.
16:45 - 18:00 | Presenter: Satheesh Chiradoni Thungappa
- Abstract
Loading... -
+
P2.10-08 - Smoking Prevention Project in School Population: My Health Is in My Own Hands
16:45 - 18:00 | Presenter: Tomi Kovacevic
- Abstract
Loading... -
+
P2.10-09 - The Beliefs, Orientation, Knowledge, Understanding, Attitudes And Treatment Access To Lung Cancer Amongst Rural Men In Nigeria
16:45 - 18:00 | Presenter: Malcolm Tagbarha
- Abstract
Loading... -
+
P2.10-10 - Lung Cancer Survival in Younger Patients (<40 Years): Analysis of Surveillance, Epidemiology and End Results Program Data
16:45 - 18:00 | Presenter: Marisa Bittoni
- Abstract
Loading... -
+
P2.10-11 - Impact of Smoking on Multiple Primary Cancers Survival – A Retrospective Analysis
16:45 - 18:00 | Author(s): Anna Maria Romaszko-Wojtowicz
- Abstract
Loading... -
+
P2.10-12 - Prevalence, Pattern and Factors Associated with Dual Tobacco Use in a Rural Community in South Eastern Nigeria
16:45 - 18:00 | Presenter: Uzochukwu Ofonakara
- Abstract
Loading... -
+
P2.10-13 - When Lung Cancer Was Rare: An Historical Study of
Prevalence from 176016:45 - 18:00 | Presenter: Luc Ollivier
- Abstract
Loading... -
+
P2.10-14 - The Evalution of Relationship Between Radon Gas and Lung Cancers in Trabzon
16:45 - 18:00 | Presenter: Fazıl Aydın
- Abstract
Loading... -
+
P2.10-15 - RADON: #1 Cause of Lung Cancer in Non-Smokers
16:45 - 18:00 | Presenter: Kelley Bush
- Abstract
Loading... -
+
P2.10-16 - Finding the Relations Between Lung Cancer and Associated Risk Factors in Pakistani Population
16:45 - 18:00 | Presenter: Arooj Fatima
- Abstract
Loading... -
+
P2.10-17 - Environmental Tobacco Smoke Exposure and EGFR Mutations in Non-Smokers with Lung Cancer: A Dose-Response Analysis of Published Data
16:45 - 18:00 | Presenter: Wenhua Liang
- Abstract
Loading...
first
prev
